Is RLMD or EQ more profitable?

Equillium's return on equity of -61.43% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relmada Therapeutics N/A -71.22% -64.46% Equillium N/A -61.43% -53.72%

Does the media prefer RLMD or EQ?

In the previous week, Relmada Therapeutics had 1 more articles in the media than Equillium. MarketBeat recorded 2 mentions for Relmada Therapeutics and 1 mentions for Equillium. Relmada Therapeutics' average media sentiment score of 0.13 beat Equillium's score of -0.17 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Equillium 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, CLYM or EQ?

Equillium has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Climb Bio N/A N/A -$59.85M -$0.78 N/A Equillium $41.10M 4.48 -$22.40M -$0.32 N/A

Is CLYM or EQ more profitable?

Climb Bio's return on equity of -31.45% beat Equillium's return on equity. Company Net Margins Return on Equity Return on Assets Climb Bio N/A -31.45% -30.39% Equillium N/A -61.43% -53.72%

Does the media refer more to CLYM or EQ?

In the previous week, Climb Bio had 1 more articles in the media than Equillium. MarketBeat recorded 2 mentions for Climb Bio and 1 mentions for Equillium. Equillium's average media sentiment score of -0.17 beat Climb Bio's score of -0.19 indicating that Equillium is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Equillium 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer EQ or ZSQR?

Equillium currently has a consensus target price of $7.57, suggesting a potential upside of 160.19%. Given Equillium's stronger consensus rating and higher possible upside, research analysts plainly believe Equillium is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Equillium 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer EQ or ZSQR?

In the previous week, Coeptis Therapeutics had 3 more articles in the media than Equillium. MarketBeat recorded 4 mentions for Coeptis Therapeutics and 1 mentions for Equillium. Coeptis Therapeutics' average media sentiment score of 0.25 beat Equillium's score of -0.17 indicating that Coeptis Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coeptis Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ACRS or EQ?

In the previous week, Aclaris Therapeutics and Aclaris Therapeutics both had 1 articles in the media. Aclaris Therapeutics' average media sentiment score of 0.50 beat Equillium's score of -0.17 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Equillium 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, EQ or OCS?

Equillium has higher revenue and earnings than Oculis. Equillium is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Equillium $41.10M 4.48 -$22.40M -$0.32 N/A Oculis $1.45M 564.61 -$119.44M -$2.13 N/A

Is EQ or OCS more profitable?

Equillium has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Equillium's return on equity. Company Net Margins Return on Equity Return on Assets Equillium N/A -61.43% -53.72% Oculis -8,460.67% -56.78% -45.62%

Does the media prefer EQ or OCS?

In the previous week, Oculis had 3 more articles in the media than Equillium. MarketBeat recorded 4 mentions for Oculis and 1 mentions for Equillium. Oculis' average media sentiment score of 1.24 beat Equillium's score of -0.17 indicating that Oculis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oculis 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Equillium (EQ) Competitors

$2.91 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$3.04 +0.14 (+4.64%)

As of 07/2/2026 07:52 PM Eastern

Compare

EQ vs. RLMD, CLYM, ZSQR, ACRS, and OCS

Should you buy Equillium stock or one of its competitors? MarketBeat compares Equillium with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Equillium include Relmada Therapeutics (RLMD), Climb Bio (CLYM), Coeptis Therapeutics (ZSQR), Aclaris Therapeutics (ACRS), and Oculis (OCS). These companies are all part of the "pharmaceutical products" industry.

How does Equillium compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Relmada Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 91.08%. Equillium has a consensus target price of $7.57, suggesting a potential upside of 160.19%. Given Equillium's stronger consensus rating and higher possible upside, analysts plainly believe Equillium is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Equillium	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 27.1% of Equillium shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by insiders. Comparatively, 17.8% of Equillium shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Equillium's return on equity of -61.43% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Equillium	N/A	-61.43%	-53.72%

In the previous week, Relmada Therapeutics had 1 more articles in the media than Equillium. MarketBeat recorded 2 mentions for Relmada Therapeutics and 1 mentions for Equillium. Relmada Therapeutics' average media sentiment score of 0.13 beat Equillium's score of -0.17 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Relmada Therapeutics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market. Comparatively, Equillium has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

Equillium has higher revenue and earnings than Relmada Therapeutics. Equillium is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Equillium	$41.10M	4.48	-$22.40M	-$0.32	N/A

Summary

Equillium beats Relmada Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Equillium compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Climb Bio has a beta of 0.07, indicating that its stock price is 93% less volatile than the broader market. Comparatively, Equillium has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 27.1% of Equillium shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by company insiders. Comparatively, 17.8% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Climb Bio currently has a consensus target price of $21.73, suggesting a potential upside of 68.43%. Equillium has a consensus target price of $7.57, suggesting a potential upside of 160.19%. Given Equillium's higher possible upside, analysts clearly believe Equillium is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Equillium	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Climb Bio's return on equity of -31.45% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
Equillium	N/A	-61.43%	-53.72%

In the previous week, Climb Bio had 1 more articles in the media than Equillium. MarketBeat recorded 2 mentions for Climb Bio and 1 mentions for Equillium. Equillium's average media sentiment score of -0.17 beat Climb Bio's score of -0.19 indicating that Equillium is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Equillium has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
Equillium	$41.10M	4.48	-$22.40M	-$0.32	N/A

Summary

Equillium beats Climb Bio on 8 of the 15 factors compared between the two stocks.

How does Equillium compare to Coeptis Therapeutics?

Equillium (NASDAQ:EQ) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Coeptis Therapeutics has lower revenue, but higher earnings than Equillium. Equillium is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	4.48	-$22.40M	-$0.32	N/A
Coeptis Therapeutics	N/A	N/A	-$11.92M	-$2.52	N/A

In the previous week, Coeptis Therapeutics had 3 more articles in the media than Equillium. MarketBeat recorded 4 mentions for Coeptis Therapeutics and 1 mentions for Equillium. Coeptis Therapeutics' average media sentiment score of 0.25 beat Equillium's score of -0.17 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coeptis Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Equillium has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -810.04%. Equillium's return on equity of -61.43% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-61.43%	-53.72%
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

Equillium currently has a consensus target price of $7.57, suggesting a potential upside of 160.19%. Given Equillium's stronger consensus rating and higher possible upside, research analysts plainly believe Equillium is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

27.1% of Equillium shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 17.8% of Equillium shares are held by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Equillium has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market.

Summary

Equillium beats Coeptis Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Equillium compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 27.1% of Equillium shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by insiders. Comparatively, 17.8% of Equillium shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Aclaris Therapeutics and Aclaris Therapeutics both had 1 articles in the media. Aclaris Therapeutics' average media sentiment score of 0.50 beat Equillium's score of -0.17 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aclaris Therapeutics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Equillium has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

Aclaris Therapeutics currently has a consensus target price of $11.50, indicating a potential upside of 106.83%. Equillium has a consensus target price of $7.57, indicating a potential upside of 160.19%. Given Equillium's higher possible upside, analysts plainly believe Equillium is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Equillium	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Equillium has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Equillium	N/A	-61.43%	-53.72%

Equillium has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$8.37M	92.81	-$64.92M	-$0.56	N/A
Equillium	$41.10M	4.48	-$22.40M	-$0.32	N/A

Summary

Equillium beats Aclaris Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Equillium compare to Oculis?

Equillium (NASDAQ:EQ) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Equillium has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, Oculis has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

27.1% of Equillium shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 17.8% of Equillium shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Equillium currently has a consensus price target of $7.57, suggesting a potential upside of 160.19%. Oculis has a consensus price target of $38.33, suggesting a potential upside of 171.48%. Given Oculis' stronger consensus rating and higher possible upside, analysts clearly believe Oculis is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Oculis had 3 more articles in the media than Equillium. MarketBeat recorded 4 mentions for Oculis and 1 mentions for Equillium. Oculis' average media sentiment score of 1.24 beat Equillium's score of -0.17 indicating that Oculis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oculis	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Equillium has higher revenue and earnings than Oculis. Equillium is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	4.48	-$22.40M	-$0.32	N/A
Oculis	$1.45M	564.61	-$119.44M	-$2.13	N/A

Equillium has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-61.43%	-53.72%
Oculis	-8,460.67%	-56.78%	-45.62%

Summary

Oculis beats Equillium on 9 of the 17 factors compared between the two stocks.

Get Equillium News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EQ vs. The Competition

Export

Metric	Equillium	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$183.99M	$3.78B	$7.18B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.51%
P/E Ratio	-9.09	21.61	28.02	24.70
Price / Sales	4.48	331.74	535.36	97.93
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	6.19	8.66	10.96	6.46
Net Income	-$22.40M	$23.81M	$3.57B	$337.01M
7 Day Performance	-3.67%	3.39%	2.12%	1.69%
1 Month Performance	-1.02%	10.81%	5.25%	3.81%
1 Year Performance	789.91%	62.61%	33.29%	23.90%

Equillium Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EQ Equillium	3.2129 of 5 stars	$2.91 flat	$7.57 +160.2%	+789.9%	$183.99M	$41.10M	N/A	40	News Coverage Gap Up High Trading Volume
RLMD Relmada Therapeutics	1.9679 of 5 stars	$6.77 -1.7%	$12.00 +77.3%	+901.6%	$710.11M	N/A	N/A	10	Gap Up
CLYM Climb Bio	2.6562 of 5 stars	$12.30 +1.0%	$21.73 +76.6%	+907.8%	$704.34M	N/A	N/A	9
ZSQR Coeptis Therapeutics	0.2146 of 5 stars	$13.38 -9.0%	N/A	+44.2%	$688.13M	$1.36M	N/A	2	News Coverage Short Interest Increase Gap Up High Trading Volume
ACRS Aclaris Therapeutics	3.1788 of 5 stars	$4.92 +1.7%	$11.50 +133.7%	+284.8%	$687.15M	$8.37M	N/A	100	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EQ) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Equillium (EQ) Competitors

EQ vs. RLMD, CLYM, ZSQR, ACRS, and OCS

How does Equillium compare to Relmada Therapeutics?

Summary

How does Equillium compare to Climb Bio?

Summary

How does Equillium compare to Coeptis Therapeutics?

Summary

How does Equillium compare to Aclaris Therapeutics?

Summary

How does Equillium compare to Oculis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EQ vs. The Competition

Equillium Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Equillium (EQ) Competitors

EQ vs. RLMD, CLYM, ZSQR, ACRS, and OCS

How does Equillium compare to Relmada Therapeutics?

Do analysts prefer RLMD or EQ?

Do insiders & institutionals have more ownership in RLMD or EQ?

Is RLMD or EQ more profitable?

Does the media prefer RLMD or EQ?

Which has more risk and volatility, RLMD or EQ?

Which has preferable earnings & valuation, RLMD or EQ?

Summary

How does Equillium compare to Climb Bio?

Which has more risk & volatility, CLYM or EQ?

Do institutionals & insiders hold more shares of CLYM or EQ?

Do analysts prefer CLYM or EQ?

Is CLYM or EQ more profitable?

Does the media refer more to CLYM or EQ?

Which has preferable valuation and earnings, CLYM or EQ?

Summary

How does Equillium compare to Coeptis Therapeutics?

Which has better earnings & valuation, EQ or ZSQR?

Does the media prefer EQ or ZSQR?

Is EQ or ZSQR more profitable?

Do analysts prefer EQ or ZSQR?

Do insiders and institutionals have more ownership in EQ or ZSQR?

Which has more risk & volatility, EQ or ZSQR?

Summary

How does Equillium compare to Aclaris Therapeutics?

Do insiders & institutionals believe in ACRS or EQ?

Does the media refer more to ACRS or EQ?

Which has more risk and volatility, ACRS or EQ?

Do analysts prefer ACRS or EQ?

Is ACRS or EQ more profitable?

Which has better valuation & earnings, ACRS or EQ?

Summary

How does Equillium compare to Oculis?

Which has more risk and volatility, EQ or OCS?

Do insiders and institutionals hold more shares of EQ or OCS?

Do analysts recommend EQ or OCS?

Does the media prefer EQ or OCS?

Which has preferable valuation and earnings, EQ or OCS?

Is EQ or OCS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EQ vs. The Competition

Equillium Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools